GoodRx and Biogen Collaborate to Help Enhance Enrollment Experience for Providers Who Have Chosen to Start Multiple Sclerosis Patients on VUMERITY®

GoodRx and Biogen Collaborate to Help Enhance Enrollment Experience for Providers Who Have Chosen to Start Multiple Sclerosis Patients on VUMERITY®

The goal of this partnership between GoodRx (NASDAQ: GDRX), a top consumer-focused digital healthcare platform, and Biogen (NASDAQ: BIIB) is to enhance the patient and healthcare professional (HCP) experience while beginning a new specialised therapy. HCPs can now locate the enrollment form and submit it to the speciality hub through Provider Mode if they have chosen to prescribe VUMERITY® (diroximel fumarate) to patients with relapse forms of multiple sclerosis (MS). GoodRx's Provider Mode, which was just unveiled, is a new experience created especially for HCPs to assist them in accessing solutions for the pharmaceuticals they recommend. In the US, there are more than a million people who have MS. It can be difficult for HCPs to start patients on specialist medicines for illnesses like MS because of the documentation involved.




Next Article

Did you find this useful?

Medigy Innovation Network

Connecting innovation decision makers to authoritative information, institutions, people and insights.

Medigy Logo

The latest News, Insights & Events

Medigy accurately delivers healthcare and technology information, news and insight from around the world.

The best products, services & solutions

Medigy surfaces the world's best crowdsourced health tech offerings with social interactions and peer reviews.


© 2024 Netspective Media LLC. All Rights Reserved.

Built on May 29, 2024 at 11:21am